Hematologic Oncology

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

The FDA has warned that treatment with duvelisib has shown a possible increased risk of death and serious adverse effects compared with ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

The FDA has granted an orphan drug designation to evorpacept, a next-generation CD47 blocker, for use as a potential therapeutic option for patients with acute myeloid leukemia.

Genmab A/S shared plans to submit a biologics license application to the FDA seeking the approval of subcutaneous epcoritamab for the treatment of patients with relapsed or refractory large B-cell lymphoma in the second half of 2022.

Ajai Chari, MD, discusses the evolving landscape and developing therapies within multiple myeloma.

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

Shared insight on treatment goals for immune thrombocytopenia and how physicians might optimally select frontline therapy.

Opening their discussion on immune thrombocytopenia (ITP), expert panelists review criteria for diagnosis and highlight differences between adult and pediatric populations.

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

The addition of orelabrutinib to sintilimab demonstrated good efficacy with a rapid time to response in patients with relapsed/refractory primary central nervous system lymphoma.

The novel and highly selective CDK9 inhibitor GFH009 demonstrated encouraging tolerability in patients with advanced, relapsed/refractory acute myeloid leukemia and lymphoma.

The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.

Dr Daniel Pollyea discusses the role of venetoclax plus an HMA agent in patients with AML and talks about some possible mechanisms of resistance to the venetoclax-HMA combination.

Teclistamab demonstrated superiority over physician’s choice of therapy for overall survival, progression-free survival, and time to next treatment in patients with relapsed/refractory multiple myeloma.

Daniel Pollyea, MD, MS, reviews the initial results from the biomarker-directed phase 2 tamibarotene trial that were presented at ASH 2020.

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Nilanjan Ghosh, MD, PhD, discusses the low toxicity levels with lisocabtagene maraleucel that were seen in patients with relapsed/refractory large B cell lymphoma in the phase 3 TRANSFORM trial.

The FDA has approved lisocabtagene maraleucel as second-line therapy for adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization for asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who were previously treated with at least 2 TKIs.

The European Medicines Agency's Committee for Medicinal Products for Human Use has unanimously recommended full marketing authorization approval of melphalan flufenamide for patients with triple-class refractory multiple myeloma.

Richard Stone, MD, and Eunice Wang, MD, share upcoming treatment advances they look forward to for patients with acute myeloid leukemia (AML).

An overview of treatment options in patients who present with IDH1/IDH2 mutations and how to manage treatment-related adverse events.